SKF7™ is Malaysia’s first-ever ingredient to receive the United States Food and Drug (US FDA) clearance as a New Dietary Ingredient (NDIN). It is expected to receive approval from the European Food Safety Authority (EFSA) as a Novel Food in 2021. SKF7™ targets metabolic syndrome and hormonal imbalances with its pharma-grade efficacy and safety.
In addition to abdominal fat reduction, SKF7™ is scientifically proven to neutralize oxidative stress, reduce diabetes, prevent premature ageing, and improve heart and reproductive health. SKF7™ is marketed in Malaysia and the Southeast Asian region under the brand name Labeesity® and continues to be successfully registered as a nutraceutical in countries across Asia, Europe and North America.